retatrutide mechanism clinical data Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and The power of three: Retatrutide's

Novel tri-agonists (targeting GLP-1, GIP, and glucagon) like retatrutide are in early development (37, 44) Adult data show that tirzepatide produces substantially greater BMI reduction than GLP-1 monotherapy (37), suggesting these agents could revolutionize pediatric treatment if found safe and effective in youth

Whether they persist or resolve with continued use is not yet fully characterised from long-term data

However, 4.5% of semaglutide trial participants and 6.2% of people on the highest tirzepatide dose (15 mg weekly) ultimately stopped the drug because of these side effects

however, it is unclear whether providers offer alternatives such as liraglutide or tirzepatide

What brought them centre stage in the public eye is, however, the dramatic weight loss they induce15-22% of baseline body weight can be shed with the use of these drugs